Heterodimeric antibodies that bind CD3 and CLDN6
US12398207B2 · kind B2 · utility
0Cited by
151References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 20, 2024 |
| Grant date | Aug 26, 2025 |
| Priority date | — |
| Expiry date | Aug 20, 2044 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K16/28
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are novel CLDN6 binding domains, and anti-CLDN6×anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.